FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

FibroGen Inc FGEN:

• FIBROGEN INITIATES PHASE 2 MONOTHERAPY TRIAL OF FG-3246, A FIRST-IN-CLASS CD46 TARGETING ADC, IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

• FIBROGEN INC - INTERIM ANALYSIS OF TRIAL EXPECTED IN 2H 2026

• FIBROGEN INC - TOPLINE RESULTS OF FG-3246 IN COMBINATION WITH ENZALUTAMIDE IN PATIENTS WITH MCRPC ENZALUTAMIDE EXPECTED Q4 2025